X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Following the promising results of a Phase 2a study showing that AEF0117 reduced the subjective effects of cannabis and cannabis self-administration in subjects with moderate to severe CUD.
Lead Product(s): AEF0117
Therapeutic Area: Psychiatry/Psychology Product Name: AEF0117
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Indivior
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
Indivior has entered into a strategic collaboration with Aelis Farma ("Aelis"), a private biotechnology company based in Bordeaux, France, that includes an exclusive option and license agreement (the "Agreement") for the global rights to AEF0117.
Lead Product(s): AEF0117
Therapeutic Area: Psychiatry/Psychology Product Name: AEF0117
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Indivior
Deal Size: $130.0 million Upfront Cash: $30.0 million
Deal Type: Collaboration June 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
